NASDAQ:AGIOAgios Pharmaceuticals Stock Price, Forecast & News

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AGIO stock has decreased by 1.1% and is now trading at $40.40.
View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Agios Pharmaceuticals.

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Agios Pharmaceuticals.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($1.31) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.05. The biopharmaceutical company had revenue of $37.30 million for the quarter, compared to analysts' expectations of $37.17 million. Agios Pharmaceuticals had a negative return on equity of 59.71% and a negative net margin of 182.49%. Agios Pharmaceuticals's revenue for the quarter was up 42.4% on a year-over-year basis. During the same period in the prior year, the company posted ($1.87) earnings per share.
View Agios Pharmaceuticals' earnings history.

14 analysts have issued 1 year price objectives for Agios Pharmaceuticals' stock. Their forecasts range from $49.00 to $82.00. On average, they expect Agios Pharmaceuticals' share price to reach $69.83 in the next year. This suggests a possible upside of 72.9% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals.

Media coverage about AGIO stock has been trending negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Agios Pharmaceuticals earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Agios Pharmaceuticals.

Some companies that are related to Agios Pharmaceuticals include Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Emergent Biosolutions (EBS), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE) and United Therapeutics (UTHR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA) and AbbVie (ABBV).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include First Trust Advisors LP (2.31%), Macquarie Group Ltd. (1.78%), Jennison Associates LLC (0.51%), Great Lakes Advisors LLC (0.47%), Peregrine Capital Management LLC (0.26%) and ZWJ Investment Counsel Inc. (0.25%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, John Maraganore, Scott Biller and Steven L Hoerter.
View institutional ownership trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, UBS Group AG, Rhenman & Partners Asset Management AB, New York State Common Retirement Fund, Trexquant Investment LP, Amalgamated Bank, Cutler Group LP, and Fernwood Investment Management LLC. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden.
View insider buying and selling activity for Agios Pharmaceuticals.

AGIO stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Great Lakes Advisors LLC, Peregrine Capital Management LLC, Macquarie Group Ltd., Assenagon Asset Management S.A., Russell Investments Group Ltd., WINTON GROUP Ltd, and Swiss National Bank. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse.
View insider buying and selling activity for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $40.40.

Agios Pharmaceuticals has a market capitalization of $2.79 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.

The official website for Agios Pharmaceuticals is www.agios.com.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]